HWA 285（丙戊茶碱）——一种用于治疗血管性痴呆和阿尔茨海默型痴呆的新型化合物。

HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type.

作者信息

Rother M, Kittner B, Rudolphi K, Rössner M, Labs K H

机构信息

HOECHST AG, HR PGU Cardiovascular Agents, Wiesbaden, Germany.

出版信息

Ann N Y Acad Sci. 1996 Jan 17;777:404-9. doi: 10.1111/j.1749-6632.1996.tb34453.x.

DOI:10.1111/j.1749-6632.1996.tb34453.x

PMID:8624121

Abstract

The pharmacological profile of HWA 285 favors its use in patients with both Alzheimer's disease (PDD) and/or vascular dementia (MID). Clinical trials showed clinically relevant, statistically significant efficacy in the domains of cognitive function, global function and activities of daily living (ADL) in both PDD and MID. HWA 285 had a prolonged symptomatic effect for at least 12 months, although therapeutic effects were seen already after the first 3 months of treatment. HWA 285 was very well tolerated for at least 1 year.

摘要

HWA 285的药理学特性使其适用于患有阿尔茨海默病（PDD）和/或血管性痴呆（MID）的患者。临床试验表明，在PDD和MID患者的认知功能、整体功能和日常生活活动（ADL）领域，HWA 285具有临床相关的、统计学上显著的疗效。HWA 285具有至少12个月的长期症状缓解作用，尽管在治疗的前3个月后就已观察到治疗效果。HWA 285至少1年内耐受性良好。